Prisys Biotechnologies

prisysbiotech.com

Prisys Biotechnologies is an innovative non-human primate (NHP) research and service company, with the integrated platform of NHP resources and preclinical pharmacology, Prisys brings specialized researches of new medicines and disease relevant technologies to the global pharmaceutical and biomedical industries in a broad range of disease areas are including immunology, inflammation, cardiovascular diseases, hematology, liver, kidney, lung, and oncology.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industry Outlook

IPA'S SUBSIDIARY, BIOSTRAND, SOLVES THE INFORMATION INTEGRATION DILEMMA (IID) FOR SYSTEMS BIOLOGY

Businesswire | May 31, 2023

news image

ImmunoPrecise Antibodies Ltd. an AI-driven biotherapeutic research and technology company, announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3D structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular,...

Read More

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

news image

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More

Medical

TARGETING CHRONIC INFECTIONS IN CYSTIC FIBROSIS, CYSTIC FIBROSIS FOUNDATION INVESTED IN FELIX BIOTECHNOLOGY

Felix Biotechnology | March 07, 2022

news image

Felix Biotechnology, a biopharmaceutical business focusing on developing first-in-class, long-lasting antibacterial medicines to treat chronic drug-resistant infections, announced that it has received a Therapeutics Development Award from the Cystic Fibrosis Foundation. The funding will aid Felix's efforts to develop a novel medication to treat chronic Pseudomonas aeruginosa lung infections. Chronic P. aeruginosa infections affect half of the persons with cystic fibrosis, many...

Read More

Cell and Gene Therapy

HAMILTON AND BIOFLUIDICA PEN NEXT GENERATION LIQUID BIOPSY PLATFORM CO-MARKETING AGREEMENT

BioFluidica, Inc. | September 28, 2022

news image

Biofluidica, Inc., and Hamilton Company, announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers to process biological samples to isolate extremely rare circulating tumor cells, circulating Leukemic cells, fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. Th...

Read More
news image

MedTech, Industry Outlook

IPA'S SUBSIDIARY, BIOSTRAND, SOLVES THE INFORMATION INTEGRATION DILEMMA (IID) FOR SYSTEMS BIOLOGY

Businesswire | May 31, 2023

ImmunoPrecise Antibodies Ltd. an AI-driven biotherapeutic research and technology company, announced that its subsidiary, BioStrand®, has successfully solved the Information Integration Dilemma (IID) by developing a unique technology design that enables their patented HYFT Technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3D structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular,...

Read More
news image

VALBIOTIS TEAMS UP WITH NESTLÉ TO REDUCE TYPE 2 DIABETES RISK

Labiotech | February 06, 2020

In a deal worth up to €67M, industry giant Nestlé Health Science will have the global rights to commercialize Valbiotis’ food supplement for lowering the rate of type 2 diabetes in people at high risk of developing the condition. Under the terms of the deal, the French biotech will receive an upfront payment of €4.7M from Nestlé, along with up to €62M in undisclosed development and sales milestone payments. The proceeds from the partnership will let Valbiotis c...

Read More
news image

Medical

TARGETING CHRONIC INFECTIONS IN CYSTIC FIBROSIS, CYSTIC FIBROSIS FOUNDATION INVESTED IN FELIX BIOTECHNOLOGY

Felix Biotechnology | March 07, 2022

Felix Biotechnology, a biopharmaceutical business focusing on developing first-in-class, long-lasting antibacterial medicines to treat chronic drug-resistant infections, announced that it has received a Therapeutics Development Award from the Cystic Fibrosis Foundation. The funding will aid Felix's efforts to develop a novel medication to treat chronic Pseudomonas aeruginosa lung infections. Chronic P. aeruginosa infections affect half of the persons with cystic fibrosis, many...

Read More
news image

Cell and Gene Therapy

HAMILTON AND BIOFLUIDICA PEN NEXT GENERATION LIQUID BIOPSY PLATFORM CO-MARKETING AGREEMENT

BioFluidica, Inc. | September 28, 2022

Biofluidica, Inc., and Hamilton Company, announced a co-marketing agreement to bring advanced Liquid Biopsy capabilities to laboratories worldwide. Biofluidica has developed the next-generation liquid biopsy platform, enabling Hamilton liquid handlers to process biological samples to isolate extremely rare circulating tumor cells, circulating Leukemic cells, fetal cells, cfDNA, and exosomes. The Biofluidica platform, LiquidScan™, integrates seamlessly into the Hamilton pipetting robots. Th...

Read More

Resources

resource image

Industrial Impact

Bruker Services & Software

Video

resource image

Cell and Gene Therapy, Industrial Impact

Biosimilars in the United States 2023–2027

Whitepaper

resource image

Industrial Impact

Bruker Services & Software

Video

resource image

Cell and Gene Therapy, Industrial Impact

Biosimilars in the United States 2023–2027

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us